• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

关于生物还原剂对含两个轴向氯原子的Pt(IV)前药还原作用的计算机理研究。

A computational mechanistic investigation into the reduction of Pt(iv) prodrugs with two axial chlorides by biological reductants.

作者信息

Ejehi Zeinab, Ariafard Alireza

机构信息

Department of Chemistry, Islamic Azad University, Central Tehran Branch, Shahrak Gharb, Tehran, Iran.

Department of Chemistry, Islamic Azad University, Central Tehran Branch, Shahrak Gharb, Tehran, Iran and School of Physical Science (Chemistry), University of Tasmania, Private Bag 75, Hobart TAS 7001, Australia.

出版信息

Chem Commun (Camb). 2017 Jan 24;53(8):1413-1416. doi: 10.1039/c6cc07834f.

DOI:10.1039/c6cc07834f
PMID:28079213
Abstract

It is widely reported that the Pt(iv) prodrugs with two axial chlorido ligands are reduced by biological reductants via a chloride-bridged inner-sphere mechanism. By contrast, in this contribution, we demonstrate that although this approach might be true for the reductants with sulphur donors, the reduction by ascorbates preferentially occurs via an outer sphere mechanism.

摘要

广泛报道称,具有两个轴向氯配体的铂(IV)前药通过氯桥连内球机制被生物还原剂还原。相比之下,在本论文中,我们证明尽管这种方法对于含硫供体的还原剂可能是正确的,但抗坏血酸盐的还原优先通过外球机制发生。

相似文献

1
A computational mechanistic investigation into the reduction of Pt(iv) prodrugs with two axial chlorides by biological reductants.关于生物还原剂对含两个轴向氯原子的Pt(IV)前药还原作用的计算机理研究。
Chem Commun (Camb). 2017 Jan 24;53(8):1413-1416. doi: 10.1039/c6cc07834f.
2
Antitumor Platinium(IV) Prodrugs: A Systematic Computational Exploration of Their Reduction Mechanism by l-Ascorbic Acid.抗肿瘤铂(IV)前药:l-抗坏血酸还原机制的系统计算研究。
Inorg Chem. 2019 Mar 18;58(6):3851-3860. doi: 10.1021/acs.inorgchem.8b03486. Epub 2019 Mar 7.
3
Dependence of the reduction products of platinum(IV) prodrugs upon the configuration of the substrate, bulk of the carrier ligands, and nature of the reducing agent.铂(IV)前药还原产物对载体配体的结构、体积和还原剂性质的依赖性。
Inorg Chem. 2012 Sep 17;51(18):9694-704. doi: 10.1021/ic300957v. Epub 2012 Aug 24.
4
Pt(IV) analogs of oxaliplatin that do not follow the expected correlation between electrochemical reduction potential and rate of reduction by ascorbate.奥沙利铂的 Pt(IV)类似物,其电化学还原电位与抗坏血酸还原速率之间的相关性不符合预期。
Chem Commun (Camb). 2012 Jan 21;48(6):847-9. doi: 10.1039/c1cc16647f. Epub 2011 Nov 29.
5
Influence of equatorial and axial carboxylato ligands on the kinetic inertness of platinum(IV) complexes in the presence of ascorbate and cysteine and within DLD-1 cancer cells.赤道和轴向羧基配体对天冬氨酸和半胱氨酸存在下及在 DLD-1 癌细胞内顺铂(IV)配合物动力学惰性的影响。
J Med Chem. 2013 Nov 14;56(21):8757-64. doi: 10.1021/jm401218n. Epub 2013 Oct 31.
6
New reduction pathways for ctc-[PtCl2(CH3CO2)2(NH3)(Am)] anticancer prodrugs.新型 ctc-[PtCl2(CH3CO2)2(NH3)(Am)] 抗癌前药还原途径。
Chem Commun (Camb). 2010 Mar 21;46(11):1842-4. doi: 10.1039/b925721g. Epub 2010 Feb 12.
7
Oxidation of 3,6-dioxa-1,8-octanedithiol by platinum(IV) anticancer prodrug and model complex: kinetic and mechanistic studies.3,6-二氧杂-1,8-辛二硫醇被铂(IV)抗癌前药和模型配合物氧化:动力学和机理研究。
J Phys Chem B. 2012 Jun 7;116(22):6522-8. doi: 10.1021/jp302600a. Epub 2012 May 22.
8
Synthesis, Structure, and Cytotoxicity of Oxaliplatin-Based Platinum(IV) Anticancer Prodrugs Bearing One Axial Fluoride.基于奥沙利铂的含一个轴向氟的铂(IV)抗癌前药的合成、结构和细胞毒性。
Inorg Chem. 2018 Jul 16;57(14):8227-8235. doi: 10.1021/acs.inorgchem.8b00706. Epub 2018 Jun 26.
9
Oxidation of anticancer Pt(II) complexes with monodentate phosphane ligands: towards stable but active Pt(IV) prodrugs.单核膦配体抗癌 Pt(II) 配合物的氧化:稳定但活性的 Pt(IV) 前药的研究。
Chem Commun (Camb). 2013 May 25;49(42):4806-8. doi: 10.1039/c3cc38416k.
10
Reduction of a platinum(iv) prodrug model by sulfur containing biological reductants: computational mechanistic elucidation.含硫生物还原剂还原铂(IV)前药模型:计算机制解释。
Chem Commun (Camb). 2018 Sep 13;54(74):10491-10494. doi: 10.1039/c8cc05682j.

引用本文的文献

1
Current Status of Novel Multifunctional Targeted Pt(IV) Compounds and Their Reductive Release Properties.新型多功能靶向 Pt(IV) 化合物的现状及其还原释放特性。
Molecules. 2024 Feb 6;29(4):746. doi: 10.3390/molecules29040746.
2
Anticancer Activity, Reduction Mechanism and G-Quadruplex DNA Binding of a Redox-Activated Platinum(IV)-Salphen Complex.一种氧化还原激活型铂(IV)-席夫碱配合物的抗癌活性、还原机制和 G-四链体 DNA 结合。
Int J Mol Sci. 2022 Dec 8;23(24):15579. doi: 10.3390/ijms232415579.
3
Computational Exploration of the Synergistic Anticancer Effect of a Multi-Action Ru(II)-Pt(IV) Conjugate.
计算探索多作用钌(II)-铂(IV)缀合物的协同抗癌作用。
Inorg Chem. 2022 Aug 15;61(32):12903-12912. doi: 10.1021/acs.inorgchem.2c02223. Epub 2022 Jul 28.
4
Theoretical Prediction of Dual-Potency Anti-Tumor Agents: Combination of Oxoplatin with Other FDA-Approved Oncology Drugs.理论预测双效抗肿瘤药物:奥沙利铂与其他 FDA 批准的肿瘤药物联合应用。
Int J Mol Sci. 2020 Jul 3;21(13):4741. doi: 10.3390/ijms21134741.